CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


TRV027Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug315 Chlorpromazine Injection Wiki 1.00
drug1657 sodium chloride 0.9% Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020141 Hemostatic Disorders NIH 0.41
D001778 Blood Coagulation Disorders NIH 0.41

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19

To determine whether the coagulopathy associated with COVID-19 infection is driven by overactivation of the renin angiotensin system (RAS)

NCT04419610 COVID Biological: TRV027 Other: sodium chloride 0.9%
MeSH:Hemostatic Disorders Blood Coagulation Disorders
HPO:Abnormality of coagulation Abnormality of the coagulation cascade

Primary Outcomes

Description: Mean change from baseline D-dimer at 7 days following administration of TRV027 or placebo.

Measure: Coagulopathy associated with COVID-19

Time: Day 3, Day 5 and Day 7

Secondary Outcomes

Description: Absolute D-Dimer - (Fibrin Equivalent units)

Measure: Markers of dysregulation of coagulation system

Time: Assessed at 3,5 and 7 days during admission

Description: platelet count (E9 /L)

Measure: Markers of dysregulation of coagulation system

Time: Assessed at 3,5 and 7 days during admission

Description: aPTT (Activated Partial Thromboplastin time) - seconds

Measure: Markers of dysregulation of coagulation system

Time: Assessed at 3,5 and 7 days during admission

Description: INR - (calculated as a ratio from aPTT)

Measure: Markers of dysregulation of coagulation system

Time: Assessed at 3,5 and 7 days during admission

Description: fibrinogen (g/L)

Measure: Markers of dysregulation of coagulation system

Time: Assessed at 3,5 and 7 days during admission

Description: Plasma Renin Mass and activity (ng/ml/h)

Measure: Markers of dysregulation of RAS

Time: Assessed at 3,5 and 7 days during admission.

Description: bilirubin (umol/L)

Measure: Markers of Haemolysis/inflammation

Time: Assessed at 3,5 and 7 days during admission.

Description: LDH u/L

Measure: Markers of Haemolysis/Inflammation

Time: Assessed at 3,5 and 7 days during admission.

Description: Haptoglobin g/L

Measure: Markers of Haemolysis/inflammation

Time: Assessed at 3,5 and 7 days during admission.

Description: Creatinine (umol/L)

Measure: Markers of organ dysregulation - kidney

Time: Assessed at 3,5 and 7 days during admission.

Description: BNP (B-type natriuetic Peptide) ng/L

Measure: Markers of dysregulation of cardiovascular system

Time: Assessed at 3,5 and 7 days during admission.

Description: Troponin ng/L

Measure: Markers of dysregulation of cardiovascular system

Time: Assessed at 3,5 and 7 days during admission.


Related HPO nodes (Using clinical trials)